伊布利特转复老年心房颤动的临床研究

Clinical research on intravenous ibutilide for immediate cardioversion of recent-onset in elderly atrial fibrillation

目的:观察新型Ⅲ类抗心律失常药物伊布利特转复老年心房颤动的有效性与安全性。方法:选择老年心房颤动患者98例,随机分成伊布利特组和胺碘酮组,伊布利特组于30min内静滴1mg伊布利特,胺碘酮组于10min内静注胺碘酮150mg。观察心房颤动的转复率及不良反应。结果:伊布利特组转复房颤的成功率高于胺碘酮组(70.2%vs52.9%,P<0.05),房颤的转复率与本次房颤发作的持续时间有关,持续时间低于24h的房颤转复率(77.7%)明显高于持续时间高于24h者(60%)。伊布利特最严重的不良反应为非持续性单形室性心动过速,发生率为12.8%。结论:伊布利特对老年房颤患者是一种安全有效的转复药物。

AIM:To observe the efficacy and safety of intravenous ibutilide for immediate cardioversion of recent-onset in elderly atrial fibrillation.METHODS:Ninety-eight patients with atrial fibrillation were randomly assigned into two groups:ibutilide group(n=47)and amiodarone group(n=51).Patients in ibutilide group received ibutilide 1 mg in 30 minutes,patients in amiodarone group received amiodarone 150 mg in 10 minutes.RESULTS:The rates of cardioversion in ibutilide group were significantly higher than those in amiodarone group.The conversion rates in patients whose atrial fibrillation had persisted within 24 hours were higher than those over 24 hours.The most serious adverse reaction of ibutilide was non sustained monomorphic ventricular tachycardia.CONCLUSION:Ibutilide is a safe and effective agent for elderly cardioversion of recent-onset atrial fibrillation.